Subscribe to RSS
DOI: 10.1055/s-0029-1210654
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York
Labelling of Interleukin-2 (IL-2) with 123-Iodine with Retention of Its Capacity to Bind to Activated Lymphocytes
Publication History
1986
Publication Date:
16 July 2009 (online)
![](https://www.thieme-connect.de/media/eced/198703/lookinside/thumbnails/10.1055-s-0029-1210654-1.jpg)
Summary
Human recombinant interleukin-2 (IL-2) was labelled with Iodine-123 using modified Bolton and Hunter method. Separation from free iodine was performed by gel filtration chromatography using a Sephadex G10 column. HPLC analysis of labelled IL-2 showed that 98% of TCA precipitable radioactivity eluted in a single peak.
The immunoreactivity of 123I-labelled IL-2 was determined by divert binding using the Fluorescence Activated Cell Sorter (FACS) and by receptor binding assay of IL-2 to activated lymphocytes.
To demonstrate in vivo binding to activated lymphocytes, 123I-labelled IL-2 was injected intravenously into a newly diagnosed diabetic BB/Wistar rat. Higher radioactivity was detected in the pancreas and in the lymph nodes of the BB/W rat compared to a normal rat.
These preliminary data show that 123I-labelled IL-2 retains its immunoreactivity and capacity to bind to activated lymphocytes both in vitro and in vivo and may be used for in vivo localization of lymphocytic infiltration in Type 1 diabetes.
Key words
Interleukin-2 - Activated lymphocytes - BB/Wistar rat - Type 1 diabetes